Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
China Trade Surplus Beats Forecasts in July as Exports Stay Strong 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls 
US Stock Futures Rise as Markets Await July Payrolls Data 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Wall Street Ends Mixed as Dow Hits Record Despite Tech Weakness 
US Job Growth Seen Picking Up in July 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Trump Unveils $3 Billion U.S. Critical Minerals Push 
Asian Currencies Steady as Markets Await U.S. Jobs Data 
US Dollar Gains as Iran Tensions, Fed Rate Hike Bets Rise 
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
